Highbridge Capital Management LLC decreased its stake in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 9.1% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 9,920 shares of the biopharmaceutical company’s stock after selling 999 shares during the period. Highbridge Capital Management LLC’s holdings in Alexion Pharmaceuticals were worth $1,379,000 at the end of the most recent reporting period.
A number of other institutional investors also recently added to or reduced their stakes in the business. First Hawaiian Bank purchased a new stake in shares of Alexion Pharmaceuticals in the third quarter valued at $102,000. Advisory Services Network LLC grew its position in shares of Alexion Pharmaceuticals by 145.3% in the second quarter. Advisory Services Network LLC now owns 883 shares of the biopharmaceutical company’s stock valued at $121,000 after purchasing an additional 523 shares during the period. Columbia Asset Management purchased a new stake in shares of Alexion Pharmaceuticals in the third quarter valued at $138,000. Checchi Capital Advisers LLC purchased a new stake in shares of Alexion Pharmaceuticals in the third quarter valued at $204,000. Finally, Integrated Wealth Concepts LLC purchased a new stake in shares of Alexion Pharmaceuticals in the third quarter valued at $205,000. 93.33% of the stock is owned by institutional investors.
A number of brokerages have recently commented on ALXN. BidaskClub raised Alexion Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday. Oppenheimer set a $165.00 price objective on Alexion Pharmaceuticals and gave the company a “buy” rating in a research report on Monday, November 26th. Credit Suisse Group set a $156.00 price objective on Alexion Pharmaceuticals and gave the company a “buy” rating in a research report on Monday, October 15th. Leerink Swann set a $181.00 price objective on Alexion Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, October 24th. Finally, Zacks Investment Research raised Alexion Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $134.00 price objective for the company in a research report on Tuesday, October 30th. Three research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $161.50.
In related news, EVP Indrani Lall Franchini sold 2,605 shares of Alexion Pharmaceuticals stock in a transaction on Wednesday, November 28th. The stock was sold at an average price of $118.13, for a total value of $307,728.65. Following the transaction, the executive vice president now owns 29,304 shares in the company, valued at $3,461,681.52. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 4.35% of the stock is currently owned by company insiders.
Shares of Alexion Pharmaceuticals stock opened at $115.60 on Friday. Alexion Pharmaceuticals, Inc. has a twelve month low of $102.10 and a twelve month high of $140.77. The firm has a market capitalization of $27.00 billion, a P/E ratio of 18.48, a PEG ratio of 1.04 and a beta of 1.02. The company has a debt-to-equity ratio of 0.32, a quick ratio of 2.74 and a current ratio of 3.16.
Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its earnings results on Wednesday, October 24th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.74 by $0.28. Alexion Pharmaceuticals had a return on equity of 16.60% and a net margin of 3.90%. The firm had revenue of $1.03 billion for the quarter, compared to analysts’ expectations of $1.02 billion. During the same quarter last year, the firm earned $1.44 earnings per share. The firm’s revenue for the quarter was up 19.5% compared to the same quarter last year. As a group, equities research analysts predict that Alexion Pharmaceuticals, Inc. will post 6.82 EPS for the current year.
ILLEGAL ACTIVITY WARNING: This news story was published by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another domain, it was stolen and reposted in violation of United States & international trademark and copyright law. The original version of this news story can be viewed at https://www.americanbankingnews.com/2018/12/08/highbridge-capital-management-llc-sells-999-shares-of-alexion-pharmaceuticals-inc-alxn.html.
About Alexion Pharmaceuticals
Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; atypical hemolytic uremic syndrome (aHUS), a genetic disease; and generalized myasthenia gravis, a debilitating, complement-mediated neuromuscular disease.
Featured Article: What is an SEC Filing?
Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.